Virpax Pharma rises as pain medication shows promise in animal study

Virpax Pharmaceuticals

10/07/2024 15:57

(Updates)
    ** Shares of drug developer Virpax Pharmaceuticals  VRPX.O 
more than double to $2.79
    ** Stock on track for best day in nearly three years if
gains hold
    ** Co announces positive results from an animal study
testing its non-addictive pain medication, probudur
    ** Co says the treatment was injected into 4 domestic pigs
at a dose of 30 mg/kg and was well-tolerated by all of the pigs 
    ** The study was designed to determine how the body reacts
to the treatment after it is administered and to ascertain any
adverse effects on the pigs
    ** Probudur is being developed to significantly reduce or
eliminate the need for opioids after surgery in approved
indications - VRPX 
    ** The experimental treatment is injected at a wound site to
provide both immediate and extended pain relief  
    ** Including session moves, stock down 10.3% YTD 

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))